Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine in Infants
NCT00381615Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2006
- Primary completion
- Jul 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal group B infection (MenB) (4 arms), sponsored by Novartis. Primary endpoints: Percentage of Subjects With Bactericidal Titers, BCA >= 1:4, Geometric Mean Bactericidal Titers Against Meningococcal Strains and 7 more. Started Sep 2006; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal group B infection (MenB)
Beyond the preview
Go deeper on NCT00381615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381615.